DEXCOM INC (DXCM) Fundamental Analysis & Valuation

NASDAQ:DXCM • US2521311074

Current stock price

61.35 USD
+1.8 (+3.02%)
At close:
61 USD
-0.35 (-0.57%)
After Hours:

This DXCM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. DXCM Profitability Analysis

1.1 Basic Checks

  • DXCM had positive earnings in the past year.
  • DXCM had a positive operating cash flow in the past year.
  • Each year in the past 5 years DXCM has been profitable.
  • DXCM had a positive operating cash flow in each of the past 5 years.
DXCM Yearly Net Income VS EBIT VS OCF VS FCFDXCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

1.2 Ratios

  • DXCM has a Return On Assets of 13.19%. This is amongst the best in the industry. DXCM outperforms 93.58% of its industry peers.
  • The Return On Equity of DXCM (30.46%) is better than 96.79% of its industry peers.
  • DXCM's Return On Invested Capital of 18.92% is amongst the best of the industry. DXCM outperforms 96.79% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for DXCM is significantly above the industry average of 9.14%.
  • The 3 year average ROIC (14.59%) for DXCM is below the current ROIC(18.92%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 13.19%
ROE 30.46%
ROIC 18.92%
ROA(3y)10.24%
ROA(5y)8.29%
ROE(3y)28.01%
ROE(5y)22.13%
ROIC(3y)14.59%
ROIC(5y)11.66%
DXCM Yearly ROA, ROE, ROICDXCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 -20 30

1.3 Margins

  • DXCM has a better Profit Margin (17.94%) than 93.05% of its industry peers.
  • DXCM's Profit Margin has declined in the last couple of years.
  • The Operating Margin of DXCM (21.55%) is better than 94.12% of its industry peers.
  • In the last couple of years the Operating Margin of DXCM has grown nicely.
  • With a decent Gross Margin value of 62.09%, DXCM is doing good in the industry, outperforming 64.17% of the companies in the same industry.
  • DXCM's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 21.55%
PM (TTM) 17.94%
GM 62.09%
OM growth 3Y15.68%
OM growth 5Y5.09%
PM growth 3Y15.23%
PM growth 5Y-8.86%
GM growth 3Y-1.61%
GM growth 5Y-1.72%
DXCM Yearly Profit, Operating, Gross MarginsDXCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. DXCM Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so DXCM is creating value.
  • Compared to 1 year ago, DXCM has less shares outstanding
  • The number of shares outstanding for DXCM remains at a similar level compared to 5 years ago.
  • Compared to 1 year ago, DXCM has an improved debt to assets ratio.
DXCM Yearly Shares OutstandingDXCM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
DXCM Yearly Total Debt VS Total AssetsDXCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • DXCM has an Altman-Z score of 6.10. This indicates that DXCM is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.10, DXCM is in the better half of the industry, outperforming 79.68% of the companies in the same industry.
  • The Debt to FCF ratio of DXCM is 1.20, which is an excellent value as it means it would take DXCM, only 1.20 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1.20, DXCM belongs to the top of the industry, outperforming 89.84% of the companies in the same industry.
  • A Debt/Equity ratio of 0.47 indicates that DXCM is not too dependend on debt financing.
  • The Debt to Equity ratio of DXCM (0.47) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 1.2
Altman-Z 6.1
ROIC/WACC2.26
WACC8.39%
DXCM Yearly LT Debt VS Equity VS FCFDXCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • DXCM has a Current Ratio of 1.88. This is a normal value and indicates that DXCM is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.88, DXCM is doing worse than 65.78% of the companies in the same industry.
  • DXCM has a Quick Ratio of 1.59. This is a normal value and indicates that DXCM is financially healthy and should not expect problems in meeting its short term obligations.
  • DXCM has a Quick ratio (1.59) which is comparable to the rest of the industry.
  • DXCM does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.59
DXCM Yearly Current Assets VS Current LiabilitesDXCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. DXCM Growth Analysis

3.1 Past

  • DXCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.27%, which is quite impressive.
  • The Earnings Per Share has been growing by 19.29% on average over the past years. This is quite good.
  • DXCM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.60%.
  • DXCM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.33% yearly.
EPS 1Y (TTM)27.27%
EPS 3Y28.82%
EPS 5Y19.29%
EPS Q2Q%75%
Revenue 1Y (TTM)15.6%
Revenue growth 3Y17.01%
Revenue growth 5Y19.33%
Sales Q2Q%15.05%

3.2 Future

  • DXCM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.44% yearly.
  • The Revenue is expected to grow by 12.44% on average over the next years. This is quite good.
EPS Next Y36.73%
EPS Next 2Y27.84%
EPS Next 3Y25.1%
EPS Next 5Y22.44%
Revenue Next Year12.62%
Revenue Next 2Y12.47%
Revenue Next 3Y12.38%
Revenue Next 5Y12.44%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DXCM Yearly Revenue VS EstimatesDXCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B 10B
DXCM Yearly EPS VS EstimatesDXCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

6

4. DXCM Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 29.21, the valuation of DXCM can be described as expensive.
  • DXCM's Price/Earnings ratio is a bit cheaper when compared to the industry. DXCM is cheaper than 71.12% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.64, DXCM is valued at the same level.
  • With a Price/Forward Earnings ratio of 20.18, DXCM is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of DXCM indicates a somewhat cheap valuation: DXCM is cheaper than 78.07% of the companies listed in the same industry.
  • DXCM's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.36.
Industry RankSector Rank
PE 29.21
Fwd PE 20.18
DXCM Price Earnings VS Forward Price EarningsDXCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, DXCM is valued a bit cheaper than the industry average as 75.40% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of DXCM indicates a rather cheap valuation: DXCM is cheaper than 85.56% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 21.92
EV/EBITDA 17.37
DXCM Per share dataDXCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • DXCM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of DXCM may justify a higher PE ratio.
  • DXCM's earnings are expected to grow with 25.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.8
PEG (5Y)1.51
EPS Next 2Y27.84%
EPS Next 3Y25.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DXCM Dividend Analysis

5.1 Amount

  • DXCM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DXCM Fundamentals: All Metrics, Ratios and Statistics

DEXCOM INC

NASDAQ:DXCM (5/1/2026, 8:22:36 PM)

After market: 61 -0.35 (-0.57%)

61.35

+1.8 (+3.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength11.18
Industry Growth59.63
Earnings (Last)04-30
Earnings (Next)07-28
Inst Owners101.29%
Inst Owner Change0.66%
Ins Owners0.25%
Ins Owner Change9.15%
Market Cap23.61B
Revenue(TTM)4.66B
Net Income(TTM)836.30M
Analysts84.86
Price Target89.21 (45.41%)
Short Float %3.97%
Short Ratio3.61
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.4%
Min EPS beat(2)-32.12%
Max EPS beat(2)5.32%
EPS beat(4)2
Avg EPS beat(4)-6.03%
Min EPS beat(4)-32.12%
Max EPS beat(4)6.77%
EPS beat(8)5
Avg EPS beat(8)-1.11%
EPS beat(12)9
Avg EPS beat(12)9.15%
EPS beat(16)11
Avg EPS beat(16)5.86%
Revenue beat(2)1
Avg Revenue beat(2)-0.14%
Min Revenue beat(2)-0.9%
Max Revenue beat(2)0.61%
Revenue beat(4)2
Avg Revenue beat(4)0.1%
Min Revenue beat(4)-0.9%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-1.02%
Revenue beat(12)5
Avg Revenue beat(12)-0.35%
Revenue beat(16)6
Avg Revenue beat(16)-0.53%
PT rev (1m)0.68%
PT rev (3m)1.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.25%
EPS NY rev (1m)0.03%
EPS NY rev (3m)1.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.09%
Valuation
Industry RankSector Rank
PE 29.21
Fwd PE 20.18
P/S 5.06
P/FCF 21.92
P/OCF 16.39
P/B 8.6
P/tB 8.91
EV/EBITDA 17.37
EPS(TTM)2.1
EY3.42%
EPS(NY)3.04
Fwd EY4.95%
FCF(TTM)2.8
FCFY4.56%
OCF(TTM)3.74
OCFY6.1%
SpS12.11
BVpS7.14
TBVpS6.89
PEG (NY)0.8
PEG (5Y)1.51
Graham Number18.3611 (-70.07%)
Profitability
Industry RankSector Rank
ROA 13.19%
ROE 30.46%
ROCE 23.93%
ROIC 18.92%
ROICexc 36.12%
ROICexgc 37.75%
OM 21.55%
PM (TTM) 17.94%
GM 62.09%
FCFM 23.11%
ROA(3y)10.24%
ROA(5y)8.29%
ROE(3y)28.01%
ROE(5y)22.13%
ROIC(3y)14.59%
ROIC(5y)11.66%
ROICexc(3y)37.89%
ROICexc(5y)31.72%
ROICexgc(3y)41.79%
ROICexgc(5y)35.48%
ROCE(3y)18.46%
ROCE(5y)14.75%
ROICexgc growth 3Y1.89%
ROICexgc growth 5Y6.96%
ROICexc growth 3Y7.33%
ROICexc growth 5Y6.44%
OM growth 3Y15.68%
OM growth 5Y5.09%
PM growth 3Y15.23%
PM growth 5Y-8.86%
GM growth 3Y-1.61%
GM growth 5Y-1.72%
F-Score8
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 1.2
Debt/EBITDA 1.03
Cap/Depr 144.36%
Cap/Sales 7.8%
Interest Coverage 88.12
Cash Conversion 114.67%
Profit Quality 128.81%
Current Ratio 1.88
Quick Ratio 1.59
Altman-Z 6.1
F-Score8
WACC8.39%
ROIC/WACC2.26
Cap/Depr(3y)145.46%
Cap/Depr(5y)210.39%
Cap/Sales(3y)7.74%
Cap/Sales(5y)10.33%
Profit Quality(3y)110.93%
Profit Quality(5y)89.33%
High Growth Momentum
Growth
EPS 1Y (TTM)27.27%
EPS 3Y28.82%
EPS 5Y19.29%
EPS Q2Q%75%
EPS Next Y36.73%
EPS Next 2Y27.84%
EPS Next 3Y25.1%
EPS Next 5Y22.44%
Revenue 1Y (TTM)15.6%
Revenue growth 3Y17.01%
Revenue growth 5Y19.33%
Sales Q2Q%15.05%
Revenue Next Year12.62%
Revenue Next 2Y12.47%
Revenue Next 3Y12.38%
Revenue Next 5Y12.44%
EBIT growth 1Y53.73%
EBIT growth 3Y35.36%
EBIT growth 5Y25.41%
EBIT Next Year67.73%
EBIT Next 3Y32.66%
EBIT Next 5Y25.77%
FCF growth 1Y70.79%
FCF growth 3Y52.34%
FCF growth 5Y31.25%
OCF growth 1Y45.6%
OCF growth 3Y29.1%
OCF growth 5Y24.81%

DEXCOM INC / DXCM Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for DEXCOM INC?

ChartMill assigns a fundamental rating of 7 / 10 to DXCM.


What is the valuation status of DEXCOM INC (DXCM) stock?

ChartMill assigns a valuation rating of 6 / 10 to DEXCOM INC (DXCM). This can be considered as Fairly Valued.


What is the profitability of DXCM stock?

DEXCOM INC (DXCM) has a profitability rating of 8 / 10.


How financially healthy is DEXCOM INC?

The financial health rating of DEXCOM INC (DXCM) is 8 / 10.